<SEC-DOCUMENT>0001213900-26-000744-index.html : 20260105
<SEC-HEADER>0001213900-26-000744.hdr.sgml : 20260105
<ACCEPTANCE-DATETIME>20260105072017
ACCESSION NUMBER:		0001213900-26-000744
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260105
FILED AS OF DATE:		20260105
DATE AS OF CHANGE:		20260105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NewcelX Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		26503891

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		PROVINCE COUNTRY:   	V8
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		PROVINCE COUNTRY:   	V8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NLS Pharmaceutics Ltd.
		DATE OF NAME CHANGE:	20190719
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0270504-6k_newcelx.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: ea0270504-6k_newcelx.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea027050401ex99-1_newcelx.htm
<DESCRIPTION>PRESS RELEASE TITLED: "NEWCELX APPOINTS DR. JULIEN BOISDRON, A SWISS BIG PHARMA LEADER IN DIABETES INNOVATION, TO ITS SCIENTIFIC ADVISORY BOARD"
<TEXT>
Document 2 - file: ea027050401ex99-1_newcelx.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 3 - file: ex99-1_001.jpg

</DOCUMENT>
</SEC-DOCUMENT>